| Title: | Genetic proxies for PCSK9 inhibition associate with lipoprotein(a): Effects on coronary artery disease and ischemic stroke |
| Journal: | Atherosclerosis |
| Published: | 26 Sep 2022 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/36244797/ |
| DOI: | https://doi.org/10.1016/j.atherosclerosis.2022.09.007 |
| URL: | https://epub.ub.uni-muenchen.de/115116/1/PIIS0021915022014332_1_.pdf |
| Citations: | 8 (7 in last 2 years) as of 8 Aug 2024 |
Publication 10480
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
BACKGROUND AND AIMS: Post hoc analyses of clinical trials show that PCSK9 inhibitors might lower lipoprotein(a), but whether this effect contributes to reductions in cardiovascular risk remains unknown. We aimed to assess whether genetically proxied PCSK9 inhibition influences lipoprotein(a) (Lp(a)), and whether any such effect could mediate its effects on coronary artery disease (CAD) and ischemic stroke (IS).</p>
METHODS: To explore associations between the genetic proxies for PCSK9 inhibitors and Lp(a) levels, we used UK Biobank data (310,020 individuals). We identified 10 variants in the PCSK9 gene associated with lower PCSK9 and LDL-C levels as proxies for PCSK9 inhibition. We explored the effects of genetically proxied PCSK9 inhibition on Lp(a) levels, as well as on odds of CAD (60,801 cases, 184,305 controls) and IS (60,341 cases, 454,450 controls) in two-sample Mendelian randomization analyses. In mediation analyses, we assessed the effects of genetically proxied PCSK9 inhibition on CAD and IS mediated through reductions in Lp(a) levels.</p>
RESULTS: Genetically proxied PCSK9 inhibition (1-SD decrement in PCSK9 concentration; corresponding to 20.6 mg/dl decrement in LDL-C levels) was associated with a 4% decrease in log-Lp(a) levels (beta: -0.038, 95%CI: -0.053 to -0.023). We estimated a 0.8% reduction in the odds for CAD (OR: 0.992, 95%CI: 0.989-0.995) and a 0.5% reduction in the odds for atherosclerotic IS (OR: 0.995, 95%CI: 0.992-0.998) due to reductions in Lp(a) levels through genetically proxied PCSK9 inhibition, corresponding to 3.8% and 3.2% of the total effects, respectively.</p>
CONCLUSIONS: Genetic proxies for PCSK9 inhibition are associated with lower Lp(a) levels. However, Lp(a) lowering explains only a small proportion of the total effects of genetic proxies for PCSK9 inhibitors on risk of CAD and IS.</p>
7 Keywords
- Cholesterol, LDL
- Coronary Artery Disease
- Humans
- Ischemic Stroke
- Lipoprotein(a)
- PCSK9 Inhibitors
- Proprotein Convertase 9
8 Authors
- Gian Marco De Marchis
- Tolga D Dittrich
- Rainer Malik
- Annaelle V Zietz
- Lilian F Kriemler
- Brian A Ference
- Martin Dichgans
- Marios K Georgakis
1 Application
| Application ID | Title |
|---|---|
| 2532 | UK Biobank Stroke Study (UKBiSS): developing an in-depth understanding of the determinants of stroke and its subtypes |
Enabling scientific discoveries that improve human health